奥马环素治疗急性细菌性皮肤及皮肤结构感染
本文整合了两项随机对照研究,比较奥马环素与利奈唑胺治疗急性细菌性皮肤及皮肤结构感染(ABSSSI)的疗效与安全性。共691例接受奥马环素、689例接受利奈唑胺。奥马环素在FDA早期临床应答终点(86.2% vs 83.9%;差异2.3,95%CI -1.5至6.2)和EMA研究者评估的治愈测试应答终点上均非劣于利奈唑胺。奥马环素治疗ABSSSI有效且安全。
要点
- 奥马环素治疗ABSSSI的早期临床应答率非劣于利奈唑胺。
- 不同感染类型及病原体所致感染的临床应答相似。
- 治疗中出现的不良事件多为轻中度,奥马环素组发生率51.1%,利奈唑胺组41.2%。
核心结论
- 奥马环素治疗急性细菌性皮肤及皮肤结构感染有效且安全。
研究设计与样本
- 整合分析两项随机对照研究(OASIS-1和OASIS-2),比较奥马环素与利奈唑胺。
- OASIS-1先静脉给药后可选序贯口服,OASIS-2为纯口服研究。
- 共691例接受奥马环素,689例接受利奈唑胺。
主要发现
- 感染类型包括伤口感染46.8%、蜂窝织炎/丹毒30.5%、大脓肿22.7%。
- 73.2%患者检出病原体,其中金黄色葡萄球菌占74.7%,MRSA占32.4%。
- FDA早期临床应答率奥马环素86.2% vs 利奈唑胺83.9%,差异2.3(95%CI -1.5至6.2)。
- 治疗中出现不良事件发生率奥马环素51.1%,利奈唑胺41.2%,多为轻中度。
关键数值与推荐
- FDA主要终点早期临床应答:奥马环素86.2% vs 利奈唑胺83.9%,差异2.3(95%CI -1.5至6.2),达到非劣效。
- EMA主要终点研究者评估的治愈测试应答:奥马环素非劣于利奈唑胺。
临床怎么用
- 奥马环素可作为ABSSSI的治疗选择之一,包括MRSA感染。
- 可根据病情选择静脉转口服或纯口服方案。
局限性
- 原文未报告具体局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Within the last decade, methicillin-resistant Staphylococcus aureus (MRSA) has emerged as a frequent cause of purulent skin and soft tissue infections. New therapeutic options are being investigated for these infections. METHODS: We report an integrated analysis of 2 randomized, controlled studies involving omadacycline, a novel aminomethylcycline, and linezolid for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Omadacycline in Acute Skin and Skin Structure Infections Study 1 (OASIS-1) initiated patients on intravenous omadacycline or linezolid, with the option to transition to an oral formulation after day 3. OASIS-2 was an oral-only study of omadacycline versus linezolid. RESULTS: In total, 691 patients received omadacycline and 689 patients received linezolid. Infection types included wound infection in 46.8% of patients, cellulitis/erysipelas in 30.5%, and major abscess in 22.7%. Pathogens were identified in 73.2% of patients. S. aureus was detected in 74.7% and MRSA in 32.4% of patients in whom a pathogen was identified. Omadacycline was noninferior to linezolid using the Food and Drug Administration primary endpoint of early clinical response (86.2% vs 83.9%; difference 2.3, 95% confidence interval -1.5 to 6.2) and using the European Medicines Agency primary endpoint of investigator-assessed clinical response at the posttreatment evaluation. Clinical responses were similar across different infection types and infections caused by different pathogens. Treatment-emergent adverse events, mostly described as mild or moderate, were reported by 51.1% of patients receiving omadacycline and 41.2% of those receiving linezolid. CONCLUSIONS: Omadacycline was effective and safe in ABSSSI. CLINICAL TRIALS REGISTRATION: NCT02378480 and NCT02877927.
引用
- Abrahamian FM, Sakoulas G, Tzanis E, et al. Omadacycline for Acute Bacterial Skin and Skin Structure Infections. Clin Infect Dis. 2019. PMID: 31367742. doi:10.1093/cid/ciz396
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。